
APYX Stock Forecast & Price Target
APYX Analyst Ratings
Bulls say
Apyx Medical is poised for continued success and growth, with its innovative products, strong revenue growth, and increasing international presence. The launch of its new FDA-cleared body contouring platform, Ayon, is expected to significantly expand its addressable market and contribute to the company's strong financial outlook. With a focus on providing high-quality technology and achieving desired patient outcomes, Apyx is well-positioned to capitalize on the growing demand for energy-based technologies in the aesthetic market. Its updated revenue guidance and ample cash reserves further support the company's positive outlook for the future.
Bears say
Apyx Medical is currently rated as a Buy due to its potential for accelerating growth and positive early momentum with its new product, Ayon. Despite not currently being profitable, the company has made efforts to control costs and has a clear path to sustainable operating profitability. However, risks to the company's growth include competition from other MedTech players, potential regulatory delays, and a highly litigious and regulated industry.
This aggregate rating is based on analysts' research of Apyx Medical Corp and is not a guaranteed prediction by Public.com or investment advice.
APYX Analyst Forecast & Price Prediction
Start investing in APYX
Order type
Buy in
Order amount
Est. shares
0 shares